-
RegMed XB is a translational product development platform that brings together Dutch and Flemish public and private stakeholders to accelerate the development of innovative regenerative therapies.
Infrastructure: RegMed XB's Pilot Factory
A seamless pathway for innovators to accelerate, de-risk, and scale regenerative therapies
read more
-
Join us in shaping the future of healthcare
Utrecht (The Netherlands), September 17th, 2024. At a joint event at the Innovation Center for Advanced Therapies (ICAT) on the Utrecht Science Park Zeist,
read more
RegMed XB welcomes Conny Helder as new Chair of the Supervisory Board
We are pleased to announce that Conny Helder will take on the role of Chair of the Supervisory Board at RegMed XB, effective September 1, 2024.
read more
Highlights from the RegMed XB 2nd Annual Conference 2024
The 2nd Annual Conference on regenerative medicine hosted by RegMed XB culminated in a highly successful gathering and attracted nearly 200 attendees.
read more -
Moonshots (research excellence)
-
Pilot Factory (infrastructure)
The RegMed XB Pilot Factory is one of the largest international infrastructures for regenerative medicine. It brings together all the expertise and infrastructure needed to bring regenerative medicine to the market.
-
RegMed XB's Ecosystem
Health Foundations
The following Dutch health foundations are involved in defining research objectives and provide guidance in the research we conduct to ensure we maintain focus on the patient.
read moreAcademic Partners
RegMed XB works together with (inter)national top-rated academic institutions and collaborates specifically and exclusively with researchers who contribute specific expertise to the Moonshot initiatives.
read moreIndustrial Partners
Partnering with companies offers access to their expertise in designing scalable and feasible products. Currently, we have strong partnerships with the following entities.
read moreGovernmental Partners
RegMed XB receives support from national and local governments to de-risk promising concepts from academia to proof of concept or initial clinical trial stages.
read more -
-
-
-
-
-
-